Immunotherapy of allergic diseases using probiotics or recombinant probiotics
Allergic diseases affect up to 30% of the western population, and their prevalence is increasing. Probiotics are able to modulate the mucosal immune response, and clinical trials demonstrated that specific strains, especially lactic acid bacteria (LAB) ones, reduce allergic symptoms. Moreover, the use of recombinant probiotics has been evaluated as possible strategies for the immunotherapy of allergic diseases. The production and delivery of allergens by recombinant LAB in concert with their ability to induce a Th1-type immune response have been shown to be a promising mucosal vaccination strategy in mouse model. The aim of this article is to review the applications of probiotics in allergy immunotherapy with a special focus on recombinant LAB delivering proteins or DNA.
Citation: J Appl Microbiol. 2013 Aug;115(2):319-33. doi: 10.1111/jam.12174. Epub 2013 Mar 13
Publication Type: Journal article
Publisher: Journal of Applied Microbiology